VECT VectivBio Holding AG

$16.85

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 8/22/2025

About VectivBio Holding AG

VectivBio Holding AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of treatments for rare conditions. The company is headquartered in Basel, Switzerland.

Website: https://vectivbio.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1836379
Address
AESCHENVORSTADT 36, BASEL, CH
Valuation
Market Cap
$1.06B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
3.62
Performance
EPS
$-2.10
Dividend Yield
—
Profit Margin
0.00%
ROE
-56.90%
Technicals
50D MA
$15.86
200D MA
$10.35
52W High
$0.00
52W Low
$0.00
Fundamentals
Shares Outstanding
63M
Target Price
$18.33
Beta
0.10

VECT EPS Estimates vs Actual

● Estimated
● Actual

VECT News & Sentiment

Apr 03, 2024 • Benzinga NEUTRAL
Robust Growth Expected In The Intestinal Pseudo Obstruction Treatment Market: Market To Grow At A Rate Of More Than 5% Through 2024-2028 As Per TBRC's Intestinal Pseudo Obstruction Treatment Global Market Report 2024
LONDON, April 03, 2024 ( GLOBE NEWSWIRE ) -- As per The Business Research Company's Intestinal Pseudo Obstruction Treatment Global Market Report 2024, the intestinal pseudo obstruction treatment market has witnessed strong growth in recent years, with the market size projected to increase from ...
Jun 26, 2023 • GlobeNewswire NEUTRAL
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals
BASEL, Switzerland, June 26, 2023 ( GLOBE NEWSWIRE ) -- VectivBio Holding AG ( "VectivBio" ) ( Nasdaq: VECT ) , a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, announced that today's extraordinary ...
Jun 26, 2023 • Benzinga NEUTRAL
VectivBio Extraordinary General Meeting of Shareholders Approved All Proposals - VectivBio Holding ( NASDAQ:VECT )
BASEL, Switzerland, June 26, 2023 ( GLOBE NEWSWIRE ) -- VectivBio Holding AG ( "VectivBio" ) VECT, a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, announced that today's extraordinary general meeting ...
Jun 21, 2023 • Benzinga SOMEWHAT-BULLISH
ALERT: The M&A Class Action Firm Continues Investigating the Merger - CHRA, QUOT, VECT, HMPT
NEW YORK, June 21, 2023 ( GLOBE NEWSWIRE ) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the "M&A Class Action Firm" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered ...
Jun 17, 2023 • PR Newswire SOMEWHAT-BULLISH
ALERT: The M&A Class Action Firm Continues Investigating the Merger - VECT, MYBF, CHRA, HMPT
NEW YORK, June 17, 2023 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC ( the "M&A Class Action Firm" ) , a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at ...
Jun 15, 2023 • Benzinga SOMEWHAT-BULLISH
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VECT, AAIC, PRTK, INFI - Arlington Asset Inv ( NYSE:AAIC ) , Infinity Pharmaceuticals ( NASDAQ:INFI )
NEW YORK, June 15, 2023 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Sentiment Snapshot

Average Sentiment Score:

0.149
49 articles with scored sentiment

Overall Sentiment:

Neutral

VECT Reported Earnings

Nov 29, 2023
Sep 30, 2023 (Pre market)
0.46 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.46
  • Whisper: —
  • Surprise %: 100.0%
Aug 30, 2023
Jun 30, 2023 (Pre market)
0.67 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.67
  • Whisper: —
  • Surprise %: 100.0%
Apr 19, 2023
Mar 31, 2023 (Pre market)
2.82 Surprise
  • Reported EPS: $2.12
  • Estimate: $-0.70
  • Whisper: —
  • Surprise %: 402.9%
Mar 01, 2023
Dec 31, 2022 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.65
  • Estimate: $-0.65
  • Whisper: —
  • Surprise %: 0.0%
Nov 30, 2022
Sep 30, 2022 (Pre market)
-0.26 Surprise
  • Reported EPS: $-0.84
  • Estimate: $-0.58
  • Whisper: —
  • Surprise %: -44.1%
Aug 31, 2022
Jun 30, 2022 (Pre market)
-0.28 Surprise
  • Reported EPS: $-0.06
  • Estimate: $0.22
  • Whisper: —
  • Surprise %: -127.3%
Apr 07, 2022
Mar 31, 2022 (Pre market)
-1.15 Surprise
  • Reported EPS: $-1.76
  • Estimate: $-0.61
  • Whisper: —
  • Surprise %: -188.5%
Oct 29, 2021
Sep 30, 2021 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.52
  • Estimate: $-0.51
  • Whisper: —
  • Surprise %: -2.0%
Sep 01, 2021
Jun 30, 2021 (Pre market)
0.0 Surprise
  • Reported EPS: $-0.49
  • Estimate: $-0.49
  • Whisper: —
  • Surprise %: 0.0%

Financials